Theorem Clinical Research

R&D Trends

AstraZeneca, Eli Lilly ink agreement for AZD3293 for Alzheimer’s disease

Wednesday, September 17, 2014 02:28 PM

AstraZeneca and Eli Lilly have inked an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.

More... »


Curie-Cancer, Inventiva partners in epigenetics for cancer

Wednesday, September 17, 2014 02:25 PM

Curie-Cancer, the body responsible for Institut Curie’s industry partnership activities, and Inventiva, a French drug discovery company focusing on therapeutic approaches involving transcription factors and epigenetic targets, have launched the Epicure project, which just has received financial backing from France’s national research agency, the ANR (Agence Nationale pour la Recherche).

More... »


Denovo Biopharma acquires late-stage oncology drug from Eli Lilly

Wednesday, September 17, 2014 02:14 PM

Denovo Biopharma, a San Diego-based, privately held biotechnology company, has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data and information.

More... »

MedGenesis, Pfizer ink agreement for Parkinson's disease

Wednesday, September 17, 2014 02:13 PM

MedGenesis Therapeutix, a Canada-based, privately held biotechnology company focused on the development and precision delivery of definitive treatments for neurologic diseases, has entered into an agreement with Pfizer, granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease.

More... »

NIH awards $64M for the understanding of cell pathways, development of new therapies

Tuesday, September 16, 2014 09:00 AM

Building on a successful three-year pilot project, the NIH has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures (LINCS).  Discovering such cell responses will improve scientists’ understanding of cell pathways and aid in the development of new therapies for many diseases.

More... »

International Progressive MS Alliance awards $28.4M in research grants

Tuesday, September 16, 2014 08:00 AM

The International Progressive MS Alliance has awarded its first round of 22 research grants to investigators in nine countries, with the goal of removing barriers to developing treatments for progressive multiple sclerosis (MS). The alliance is a worldwide collaborative focused on finding solutions to progressive forms of multiple sclerosis that have so far eluded the scientific community.

More... »

Synergistix, MedPro Systems partner

Tuesday, September 16, 2014 07:55 AM

Synergistix, a Sunrise, Fla.-based provider of customer relationship management (CRM) solutions for life sciences, has partnered with MedPro Systems, an Arlington, N.J.-based healthcare licensing solution for pharmaceutical and device industries.

More... »

Cellerant awarded $47.5M for development of CLT-008 for acute radiation syndrome

Friday, September 12, 2014 01:16 PM

Cellerant Therapeutics, a California biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, has been awarded $47.5 million under a second option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the office of the assistant secretary for preparedness and response of the department of Health and Human Services.

More... »

Gates Foundation commits $50M to support emergency response to Ebola

Friday, September 12, 2014 01:13 PM

The Bill & Melinda Gates Foundation plans to commit $50 million to support the scale up of emergency efforts to contain the Ebola outbreak in West Africa and interrupt transmission of the virus.

More... »

PhRMA: 44 medicines and vaccines in development for HIV/AIDS

Friday, September 12, 2014 01:13 PM

America’s biopharmaceutical research companies currently are developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Washington, D.C.-based Pharmaceutical Research and Manufacturers of America (PhRMA). A second report, The Value of Innovation in HIV/AIDS Therapy, a PhRMA-sponsored white paper by Boston Healthcare Associates (BHA), highlights the progress in HIV/AIDS treatment and its impact on patients afflicted with the disease. 

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private ἀnancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs